Immunotherapy plus targeted brain radiation for lung cancer
Part of Cancer, Lungs & breathing clinical trials.
This Phase 2 trial studies whether giving immunotherapy along with a precise form of brain radiation can control brain metastases from non-small cell lung cancer. It may help by shrinking or stabilizing spots in the brain while your body’s immune system is also activated.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be age 18 or older when you sign consent
- Have non-small cell lung cancer confirmed by tissue testing
- Have brain metastases but not feeling sick from them (asymptomatic)
- Your lung cancer test must be negative for EGFR, ALK, or ROS1 gene changes
- Have 1 to 4 brain metastasis spots, with the largest spot no bigger than 4 cm
- You must be able to take chemotherapy (no known contraindications) and you cannot be pregnant or breastfeeding
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of a targeted immunotherapy drug (cadonilimab) with a precise type of radiation to treat brain tumors that have grown after initial lung cancer treatment. The goal is to see if this approach can safely shrink brain metastases and improve outcomes.
This Phase 3 study tests whether immunotherapy or targeted medicine, with or without a one-time focused brain radiation procedure, can control brain metastases from melanoma or non-small cell lung cancer. It mainly enrolls people who have no (or minimal) brain symptoms and are newly diagnosed in the brain (except for certain recent brain surgery).
This trial tests a combination of focused radiation (stereotactic radiosurgery) and an oral targeted therapy called anlotinib for people with non-small cell lung cancer that has spread to the brain. It may offer a way to control brain metastases without more invasive procedures.
This study tests whether giving radiation therapy (called stereotactic radiotherapy) to the brain before or along with a combination of an experimental drug (ivonescimab) and chemotherapy can help treat non-small cell lung cancer that has spread to the brain. It compares this approach to just receiving the drug and chemotherapy without the brain radiation.
This trial tests whether adding nitroglycerin (a medicine that widens blood vessels) to standard whole-brain radiation helps improve treatment for lung cancer that has spread to the brain. It is for people with a specific gene change (EGFR mutation) in their cancer.
This study tests a combination of a new immunotherapy drug (ivonescimab), standard chemotherapy, and focused radiation (stereotactic radiosurgery) for non-small cell lung cancer that has spread to the brain. The goal is to see if this combination can shrink tumors in both the lungs and brain.
Hear when a new Non Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.